Strategic Research and Innovation Agenda 2019-2022


The Strategic Research and Innovation Agenda (SRIA) will define strategic priorities and objectives of the infrastructure for the period 2019-2022. The development of the agenda started in the summer 2017, driven by the Executive Board of the Coordination and Support Office (C&S), in close collaboration with the Board of National Directors (BoND) and Platform Chairs (PC). A draft will be presented to the EATRIS Board of Governors (BoG) in the end of May 2018. The final SRIA is expected to be approved by the BoG in November 2018 and be effective as of January 1st 2019.

As a first step in the preparation of the SRIA, EATRIS conducted a series of interviews with a range of key internal and external stakeholders, who represent the main user groups of the infrastructure: academics, pharma industry, SME’s, and charities. Those interviews helped collect additional input on the most important trends in the field and the pressing bottlenecks as well as explore how the infrastructure could serve users’ needs better in the future.

As a result, EATRIS designed a SWOT analysis, highlighting the strengths, weaknesses of the organisation as well as opportunities and threats for the future. Following this exercise, the core writing group composed of C&S members, BoND and PC representatives agreed in April 2018 on the following structure for the SRIA.

(Please note that the draft SRIA presented below is subject to approval of EATRIS BoG and is subject to change)

  1. Reinforce the infrastructure’s academic credentials
  • Select key scientific priorities which support the development of novel tools;
  • Provide a robust framework facilitating collaborative initiatives around quality, harmonisation and reproducibility;
  • Form flexible disease task forces to support specific needs of the infrastructure;
  • Provide the new generation of researchers opportunities to participate in high potential projects.
  1. Create an effective translational medicine ecosystem
  • Engage with key stakeholders in various sectors: academic community, industry, policy makers, citizens particularly the patients community;
  • Strengthen EATRIS Community-building by reinforcing national nodes’ capacities and their integration into the translational medicine national ecosystems;
  • Work with international partners and extend alliances beyond Europe;
  • Provide support to policy-makers and increase interactions with patient organisations (according to principles of Responsible Research and Innovation).
  1. Synergise activities and services with other Health Research Infrastructures
  • Develop joint services and federate activities with RI’s (initially with BBMRI-ERIC, ECRIN-ERIC and ELIXIR), particularly in the fields of:

– Quality and standards

– Advocacy and public awareness

– Education and Training

  1. Raise awareness of EATRIS and translational medicine
  • Develop a comprehensive communication strategy addressing the key following aspects:

– Marketing towards internal stakeholders

– User engagement

– Engagement towards society through the patients community

Further updates will be provided on this page throughout the year. For more information, please contact Toni Andreu:


Website by Lewis+Humphreys